News Sentiment

NUVL sentiment intelligence

Nuvalent Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 123.96 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.0% over one week, +0.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Deerfield holders cash out of Nuvalent (NUVL) at $124 per share

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend active 0.4% over four weeks
Fair value 50.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 48
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 26
TradingView 7
Market source 6
simplywall.st 5
MT Newswires 2
Insider Monkey 2
CNBC 2
Investing.com Australia 1

Event Lens

What the news is about

Classified themes
Market update 31
Deals and strategy 19
Earnings 12
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 64
Stock Titan Direct company coverage

Deerfield group reports 0% ownership in Nuvalent (NUVL) Class A shares

A Deerfield-affiliated investor group, led by James E. Flynn, has filed an amended Schedule 13G (Amendment No. 7) for Nuvalent, Inc. (NUVL). The filing indicates that the group now beneficially owns 0 shares of Nuvalent Class A common stock, translating to 0.0% of the class. This

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Nuvalent, Inc. Insider Trading Activity

Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, reported significant merger-related equity transactions. These involved the tender of 17,017 shares of Class A Common Stock at $124.00 per share as part of a tender offer by a GlaxoSmithKline affiliate, which was followed

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent, Inc. (NUVL) CEO equity converted in $124 GSK tender offer

Nuvalent, Inc.'s President and CEO, James Richard Porter, converted all his equity holdings, including 203,529 Class A shares, RSUs, PSUs, and stock options, into cash as part of a tender offer and subsequent merger with an affiliate of GSK plc. The shares were tendered at $124.0

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent, Inc. (NUVL) director tenders stock in $124 GSK cash buyout

Nuvalent, Inc. director Sapna Srivastava has disposed of equity tied to a cash tender offer and merger with a GlaxoSmithKline affiliate. She tendered 5,146 shares of Class A Common Stock at $124.00 per share, and had 3,444 restricted stock units and several stock option grants ca

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent, Inc. (NUVL) CFO details tender offer and award cash-outs

Nuvalent, Inc. CFO Alexandra Balcom reported significant equity transactions stemming from a merger with a GlaxoSmithKline affiliate. She tendered 44,433 shares for $124.00 per share and saw restricted stock units and stock options cancelled and converted into cash at the same of

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NASDAQ: NUVL) director logs $124 tender-offer disposals

Nuvalent Director Wheeler Cameron reported the disposition of 5,146 Class A shares at $124.00 each, along with 3,444 RSUs and several stock option grants, related to GlaxoSmithKline's tender offer and subsequent merger. These transactions resulted in Cameron's reported holdings i

Tone
Positive 70/100
Event
Deals and strategy
Published
15 Jul 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NUVL) director exits equity as GSK affiliate pays $124 per share

Nuvalent's director, Grant C. Bogle, cashed out his equity holdings in connection with the company's acquisition by a GlaxoSmithKline affiliate. The acquisition involved a tender offer at $124.00 per share, resulting in Nuvalent becoming a wholly owned subsidiary. Bogle disposed

Tone
Positive 66/100
Event
Deals and strategy
Published
15 Jul 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NUVL) director equity cashed out in $124 GSK buyout

Nuvalent's director, Anna Protopapas, reported dispositions of her equity holdings in connection with GlaxoSmithKline's tender offer to acquire all outstanding Nuvalent stock for $124.00 per share. Her 5,146 Class A shares, 3,444 restricted stock units, and multiple stock options

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 22:10
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NASDAQ: NUVL) moves to remove Class A stock from Nasdaq

Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 25 to delist its Class A Common Stock from the Nasdaq Stock Market LLC, indicating a voluntary withdrawal from listing and registration under Section 12(b) of the Securities Exchange Act of 1934. This action signifies that both Nasda

Tone
Negative 38/100
Event
Market update
Published
15 Jul 2026 13:43
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NASDAQ: NUVL) tender offer clears $124 cash merger path

Nuvalent, Inc. announced the final results of the tender offer by Harmony Row Acquisition Co., a subsidiary of GlaxoSmithKline LLC, to acquire all outstanding shares for $124.00 per share. Approximately 91.3% of Nuvalent's shares were validly tendered, satisfying the minimum tend

Tone
Positive 67/100
Event
Deals and strategy
Published
15 Jul 2026 12:43
Source
Stock Titan
Investing.com Australia Direct company coverage

Nuvalent CSO Henry Pelish sells $261,362 in stock By Investing.com

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of Class A Common Stock for $261,362, executed under a Rule 10b5-1 trading plan to cover tax obligations. This sale occurred as Nuvalent shares approached a 52-week high, coinciding with GSK's announced acqui

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 02:39
Source
Investing.com Australia
Investing.com Direct company coverage

Nuvalent CSO Henry Pelish sells $261,362 in stock

Nuvalent's Chief Scientific Officer, Henry E. Pelish, sold 2,111 shares of the company's Class A Common Stock for $261,362 on July 9, 2026. This transaction was part of a pre-established trading plan, often used to cover tax obligations from equity awards, and occurred as Nuvalen

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:10
Source
Investing.com
Stock Titan Direct company coverage

Nuvalent, Inc. (NUVL) — HSR waiting period cleared; $124/ share cash offer remains subject to closing conditions

Nuvalent, Inc. (NUVL) announced that the Hart-Scott-Rodino (HSR) Act waiting period for its tender offer with Harmony Row Acquisition Co./GlaxoSmithKline LLC expired on July 9, 2026. This satisfies one key closing condition for the $124 per share cash offer, though the overall of

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent Inc. (NUVL) — GSK’s Harmony Row clears HSR; $124 cash offer proceeds

The article reports that the HSR waiting period for GSK’s Harmony Row Acquisition Co.'s tender offer to acquire Nuvalent Inc. (NUVL) has expired, satisfying a key regulatory condition. Harmony Row Acquisition Co., GlaxoSmithKline LLC, and GSK plc are offering $124.00 per share in

Tone
Positive 71/100
Event
Deals and strategy
Published
10 Jul 2026 13:11
Source
Stock Titan
Stock Titan Direct company coverage

NUVL (NASDAQ: NUVL) insider sale notice for 2,111 Class A shares

Nuvalent, Inc. (NASDAQ: NUVL) has filed a Form 144 indicating a proposed sale of 2,111 shares of Class A Common Stock, valued at $261,358.43, related to Restricted Stock Unit Vesting on July 9, 2026. The filing also revealed that 3,093 shares, totaling $323,169.86, were sold in t

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 08:41
Source
Stock Titan
Investing.com India Direct company coverage

Nuvalent president and CEO Porter sells $3.7m in shares By Investing.com

Nuvalent (NASDAQ:NUVL) President and CEO James Richard Porter sold 30,000 shares of Class A Common Stock for approximately $3.71 million on July 6, 2026, while concurrently exercising options to acquire 30,000 shares. This transaction occurred as the stock traded near its 52-week

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 23:11
Source
Investing.com India
Stock Titan Direct company coverage

Nuvalent (NUVL) CEO executes 30K-share option exercise and open-market sale under 10b5-1 plan

Nuvalent, Inc. President and CEO James Richard Porter executed a pre-planned transaction, exercising options for 30,000 shares of Class A Common Stock at $18.93 per share and simultaneously selling those 30,000 shares in the open market at a weighted average price of $123.72 per

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

FMR LLC discloses 1,417,590 shares in Nuvalent (NASDAQ: NUVL)

FMR LLC has filed an Amendment No. 5 to Schedule 13G/A, revealing a beneficial ownership of 1,417,590.47 shares of Nuvalent Inc. Class A common stock, which accounts for 1.9% of the total class. The filing indicates sole voting power over 1,402,750 shares and sole dispositive pow

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 14:09
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NUVL) supplements disclosures as $124 cash offer proceeds

Nuvalent, Inc. amended its Schedule 14D-9 to provide supplementary disclosures regarding the recommended $124.00 per share cash tender offer by a GlaxoSmithKline subsidiary. This amendment includes additional financial details, management forecasts, and Centerview valuation analy

Tone
Positive 63/100
Event
Balance sheet
Published
07 Jul 2026 19:09
Source
Stock Titan
Stock Titan Direct company coverage

Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan

Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:12
Source
Stock Titan